Parnell Pharmaceuticals Holdings Ltd (PARNF)
USD 0.11
(120.0%)
USD 0.11
(120.0%)
| Breakdown | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 5452.58 | -4759.34 | 2268.14 | -1.61 Million | -1.85 Million | -12.11 Million |
| Net Income | -1419.59 | -15.06 Thousand | -7182.16 | 129.62 Thousand | -23.12 Million | -21.69 Million |
| Depreciation & Amortization | 5367.63 | 1159.37 | 1726.00 | 2.65 Million | 7.95 Million | 2.62 Million |
| Deferred income taxes | - | - | - | -4.76 Million | 3.14 Million | 1.01 Million |
| Stock-based compensation | - | - | 466.05 | - | 303.3 Thousand | 2.04 Million |
| Change in working capital | -1714.92 | -4255.71 | -782.67 | -4.84 Million | 4.75 Million | 4.19 Million |
| Other non-cash items | 3219.47 | 13.39 Thousand | 8040.91 | 5 Million | 8.26 Million | 708.47 Thousand |
| Investing Cash Flow | -4165.26 | -3351.30 | -2740.72 | -2.75 Million | -2.53 Million | -5.08 Million |
| Investments in PPE | -891.53 | -736.37 | -828.17 | -2.75 Million | -2.53 Million | -5.08 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -3273.73 | -2614.94 | -1912.54 | - | -2.02 Million | -4.52 Million |
| Financing Cash Flow | 67.11 | 9428.08 | 993.04 | 6.15 Million | -23.41 Thousand | 19.96 Million |
| Debt repayment | -626.97 | -13.5 Thousand | -993.04 | -35.21 Million | -2.57 Million | -17.88 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 8.96 Million |
| Other Financing Activities | -559.86 | -4074.75 | - | 41.36 Million | 2.55 Million | 28.88 Million |
| Accounts receivables | 659.56 | -647.20 | -1233.23 | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 59.98 | -1824.03 | 1356.77 | -936.38 Thousand | 1.36 Million | -195.96 Thousand |
| Other working capital | -2434.47 | -1784.49 | -906.21 | -3.91 Million | 3.39 Million | 4.39 Million |
| Cash at beginning of period | 4028.24 | 4510.44 | 4400.65 | 2.37 Million | 7.11 Million | 5.66 Million |
| Cash at end of period | 4483.21 | 4028.24 | 4510.44 | 4.4 Million | 2.37 Million | 7.11 Million |
| Capital Expenditure | -891.53 | -736.37 | -828.17 | -2.75 Million | -2.53 Million | -5.08 Million |
| Effect of forex changes on cash | -899.46 | -1799.64 | -410.67 | 239.97 Thousand | -325.13 Thousand | -1.31 Million |
| Net cash flow / Change in cash | 454.97 | -482.20 | 109.80 | 2.02 Million | -4.73 Million | 1.44 Million |
| Free Cash Flow | 4561.05 | -5495.71 | 1439.96 | -4.37 Million | -4.38 Million | -17.19 Million |
| Breakdown | 2021 FY | 2020 FY | 2019 FY | 2018 FY | 2017 FY | 2016 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -1419.59 | -15.06 Thousand | -7182.16 | 129.62 Thousand | -23.12 Million | -21.69 Million |
| Depreciation & Amortization | 2535.94 | 1159.37 | 1726.00 | 2.65 Million | 7.95 Million | 2.62 Million |
| Deferred income taxes | - | - | - | -4.76 Million | 3.14 Million | 1.01 Million |
| Stock-based compensation | - | - | 466.05 | - | 303.3 Thousand | 2.04 Million |
| Change in working capital | -1714.92 | -4255.71 | -782.67 | -4.84 Million | 4.75 Million | 4.19 Million |
| Other non-cash items | 6051.15 | 13.39 Thousand | 8040.91 | 5 Million | 8.26 Million | 708.47 Thousand |
| Investing Cash Flow | -4165.26 | -3351.30 | -2740.72 | -2.75 Million | -2.53 Million | -5.08 Million |
| Investments in PPE | -891.53 | -736.37 | -828.17 | -2.75 Million | -2.53 Million | -5.08 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -3273.73 | -2614.94 | -1912.54 | - | -2.02 Million | -4.52 Million |
| Financing Cash Flow | 67.11 | 9428.08 | 993.04 | 6.15 Million | -23.41 Thousand | 19.96 Million |
| Debt repayment | -626.97 | -13.5 Thousand | -993.04 | -35.21 Million | -2.57 Million | -17.88 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 8.96 Million |
| Other Financing Activities | -559.86 | -4074.75 | - | 41.36 Million | 2.55 Million | 28.88 Million |
| Accounts receivables | 659.56 | -647.20 | -1233.23 | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | 59.98 | -1824.03 | 1356.77 | -936.38 Thousand | 1.36 Million | -195.96 Thousand |
| Other working capital | -2434.47 | -1784.49 | -906.21 | -3.91 Million | 3.39 Million | 4.39 Million |
| Cash at beginning of period | 4028.24 | 4510.44 | 4400.65 | 2.37 Million | 7.11 Million | 5.66 Million |
| Cash at end of period | 4483.21 | 4028.24 | 4510.44 | 4.4 Million | 2.37 Million | 7.11 Million |
| Capital Expenditure | -891.53 | -736.37 | -828.17 | -2.75 Million | -2.53 Million | -5.08 Million |
| Effect of forex changes on cash | -899.46 | -1799.64 | -410.67 | 239.97 Thousand | -325.13 Thousand | -1.31 Million |
| Net cash flow / Change in cash | 454.97 | -482.20 | 109.80 | 2.02 Million | -4.73 Million | 1.44 Million |
| Free Cash Flow | 4561.05 | -5495.71 | 1439.96 | -4.37 Million | -4.38 Million | -17.19 Million |
3321
3069
0535
000039
4973
SUPREMEINF